Serum soluble fas levels in ovarian cancer

Obstetrics and Gynecology

Volumn 96, Issue 1, 2000, Pages 65-69

  Hefler, Lukas ^a   Mayerhofer, Klaus ^b   Nardi, Alessandra ^b   Reinthaller, Alexander ^b   Kainz, Christian ^b   Tempfer, Clemens ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; FAS ANTIGEN; TUMOR MARKER;

AGED; APOPTOSIS; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CYST; PRIORITY JOURNAL; REGRESSION ANALYSIS;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANTIGENS, CD95; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; OVARIAN CYSTS; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 0034034661     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(00)00840-1     Document Type: Article

References (21)

1. Nagata S., Goldstein P. The Fas death factor. Science. 267:1995;1449-1456.
2. Rowe P.M. Glimmers of clinical relevance for Fas. Lancet. 347:1996;1398.
3. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science. 267:1995;1456-1462.
4. Carson D.A., Ribeiro J.M. Apoptosis and disease. Lancet. 341:1993;1251-1254.
5. Suda T., Takahashi T., Goldstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1993;1169-1178.
6. Gratas C., Tohma Y., Barnas C., Taniere P., Hainaut P., Ohgaki H. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res. 58:1998;2057-2062.
7. Nagata S. Apoptosis by death factor. Cell. 88:1997;355-365.
8. Ashkenazi A., Dixit V.M. Death receptors Signaling and modulation . Science. 281:1998;1305-1308.
9. Ghahremani M., Foghi A., Dorrington J.H. Activation of Fas ligand/receptor system kills ovarian cancer cell lines by an apoptotic mechanism. Gynecol Oncol. 70:1998;275-281.
10. Cheng J., Zhou T., Liu C., Shapiro J.P., Brauer M.J., Kiefer M.C., et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 263:1994;1759-1762.
11. Mizutani Y., Yoshida O., Bonavida B. Prognostic significance of soluble Fas in the serum of patients with bladder cancer. J Urol. 160:1998;571-576.
12. Yufu Y., Choi I., Hirase N., Tokoro A., Noguchi Y., Goto T., et al. Soluble Fas in the serum of patients with non-Hodgkin's lymphoma Higher concentrations in angioimmunoblastic T-cell lymphoma . Am J Hematol. 58:1998;34-36.
13. Munker R., Midis G., Owen-Schaub L., Andreff M. Soluble FAS (CD95) is not elevated in the serum of patients with myeloid leukemias, myeloproliferative and myelodysplastic syndromes. Leukemia. 10:1996;1531-1533.
14. Midis G.P., Shen Y., Owen-Schaub L.B. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res. 56:1996;3870-3874.
15. Kimura M., Tomita Y., Imai T., Saito T., Katagiri A., Tanikawa T., et al. Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients. Br J Cancer. 80:1999;1648-1651.
16. Wakahara Y., Nawa A., Okamoto T., Hayakawa A., Kikkawa F., Suganama N., et al. Combination effect of anti-Fas antibody and chemotherapeutic drugs in ovarian cancer cells in vitro. Oncology. 54:1997;48-54.
17. Baldwin R.L., Tran H., Karlan B.Y. Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis. Gynecol Oncol. 74:1999;265-271.
18. Kenemans P., Bon G.G., Kessler A.C., Verstraeten A.A., van Kamp G.J. Multicenter technical and clinical evaluation of a fully automated enzyme immunoassay for CA 125. Clin Chem. 38:1992;1466-1471.
19. Gutierrez L.S., Eliza M., Niven-Fairchild T., Naftolin F., Mor G. The Fas/Fas-ligand system A mechanism for immune evasion in human breast carcinomas . Breast Cancer Res Treat. 54:1999;245-253.
20. Jodo S., Kobayashi S., Nakajima Y., Matsunaga T., Nakayama N., Ogura N., et al. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin Exp Immunol. 112:1998;166-171.
21. Ghahremani M., Foghi A., Dorrington J.H. Etiology of ovarian cancer A proposed mechanism . Med Hypotheses. 52:1999;23-26.